【万泰生物:九价HPV疫苗启动男性III期临床试验并完成首例受试者入组】金十数据4月14日讯,万泰生物公告,公司九价HPV疫苗已启动男性III期临床试验,并完成首例受试者入组。该疫苗覆盖HPV16/18/31/33/45/52/58七种高危型和HPV6/11两种低危型,适用于预防由HPV6/11/16/18/31/33/45/52/58型所致的生殖器疣、阴茎/会阴/肛周癌等。试验主要目的是评价九价HPV疫苗在中国18~45周岁男性人群中的有效性、免疫原性和安全性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.